Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.423
+0.041 (10.54%)
Nov 8, 2024, 2:26 PM EST - Market open

Citius Pharmaceuticals Income Statement

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Jun '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 2018 - 2014
Selling, General & Admin
29.221.9115.6611.298.97
Upgrade
Research & Development
11.8714.8217.6612.248.818.6
Upgrade
Operating Expenses
41.0736.7333.3223.5317.7115.6
Upgrade
Operating Income
-41.07-36.73-33.32-23.53-17.71-15.6
Upgrade
Interest Expense
----0.01-0.02-0.02
Upgrade
Interest & Investment Income
0.971.180.250.260.070.05
Upgrade
Other Non Operating Income (Expenses)
----0.11-
Upgrade
EBT Excluding Unusual Items
-40.1-35.55-33.06-23.28-17.55-15.56
Upgrade
Gain (Loss) on Sale of Assets
2.393.59----
Upgrade
Other Unusual Items
---0.23--
Upgrade
Pretax Income
-37.72-31.97-33.06-23.05-17.55-15.56
Upgrade
Income Tax Expense
0.580.580.58---
Upgrade
Net Income
-38.29-32.54-33.64-23.05-17.55-15.56
Upgrade
Preferred Dividends & Other Adjustments
1.471.15-1.45--
Upgrade
Net Income to Common
-39.77-33.69-33.64-24.51-17.55-15.56
Upgrade
Shares Outstanding (Basic)
1631511461093920
Upgrade
Shares Outstanding (Diluted)
1631511461093920
Upgrade
Shares Change (YoY)
9.86%3.57%34.52%177.28%94.25%87.87%
Upgrade
EPS (Basic)
-0.24-0.22-0.23-0.23-0.45-0.77
Upgrade
EPS (Diluted)
-0.24-0.22-0.23-0.23-0.45-0.77
Upgrade
Free Cash Flow
-29.09-29.06-28.36-24.26-16.93-12.44
Upgrade
Free Cash Flow Per Share
-0.18-0.19-0.19-0.22-0.43-0.62
Upgrade
EBITDA
-41.07-36.73-33.31-23.53-17.71-15.6
Upgrade
D&A For EBITDA
000000
Upgrade
EBIT
-41.07-36.73-33.32-23.53-17.71-15.6
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.